These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 19669651)

  • 1. Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease.
    Neumann M; Roeber S; Kretzschmar HA; Rademakers R; Baker M; Mackenzie IR
    Acta Neuropathol; 2009 Nov; 118(5):605-16. PubMed ID: 19669651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy.
    Page T; Gitcho MA; Mosaheb S; Carter D; Chakraverty S; Perry RH; Bigio EH; Gearing M; Ferrer I; Goate AM; Cairns NJ; Thorpe JR
    J Mol Neurosci; 2011 Nov; 45(3):409-21. PubMed ID: 21603978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies.
    Lashley T; Rohrer JD; Bandopadhyay R; Fry C; Ahmed Z; Isaacs AM; Brelstaff JH; Borroni B; Warren JD; Troakes C; King A; Al-Saraj S; Newcombe J; Quinn N; Ostergaard K; Schrøder HD; Bojsen-Møller M; Braendgaard H; Fox NC; Rossor MN; Lees AJ; Holton JL; Revesz T
    Brain; 2011 Sep; 134(Pt 9):2548-64. PubMed ID: 21752791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The spectrum and severity of FUS-immunoreactive inclusions in the frontal and temporal lobes of ten cases of neuronal intermediate filament inclusion disease.
    Armstrong RA; Gearing M; Bigio EH; Cruz-Sanchez FF; Duyckaerts C; Mackenzie IR; Perry RH; Skullerud K; Yokoo H; Cairns NJ
    Acta Neuropathol; 2011 Feb; 121(2):219-28. PubMed ID: 20886222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic variability within the inclusion body spectrum of basophilic inclusion body disease and neuronal intermediate filament inclusion disease in frontotemporal lobar degenerations with FUS-positive inclusions.
    Gelpi E; Lladó A; Clarimón J; Rey MJ; Rivera RM; Ezquerra M; Antonell A; Navarro-Otano J; Ribalta T; Piñol-Ripoll G; Pérez A; Valldeoriola F; Ferrer I
    J Neuropathol Exp Neurol; 2012 Sep; 71(9):795-805. PubMed ID: 22892522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases.
    Cairns NJ; Uryu K; Bigio EH; Mackenzie IR; Gearing M; Duyckaerts C; Yokoo H; Nakazato Y; Jaros E; Perry RH; Arnold SE; Lee VM; Trojanowski JQ
    Acta Neuropathol; 2004 Sep; 108(3):213-23. PubMed ID: 15170578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatial patterns of FUS-immunoreactive neuronal cytoplasmic inclusions (NCI) in neuronal intermediate filament inclusion disease (NIFID).
    Armstrong RA; Gearing M; Bigio EH; Cruz-Sanchez FF; Duyckaerts C; Mackenzie IR; Perry RH; Skullerud K; Yokoo H; Cairns NJ
    J Neural Transm (Vienna); 2011 Nov; 118(11):1651-7. PubMed ID: 21792670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basophilic inclusions and neuronal intermediate filament inclusions in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.
    Ito H
    Neuropathology; 2014 Dec; 34(6):589-95. PubMed ID: 24673472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
    Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
    Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An autopsy case report of neuronal intermediate filament inclusion disease presenting with predominantly upper motor neuron features.
    Murakami A; Nakamura M; Nakamura Y; Kaneko S; Yakushiji Y; Kusaka H
    Neuropathology; 2021 Oct; 41(5):357-365. PubMed ID: 34309938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FUS/TLS-immunoreactive neuronal and glial cell inclusions increase with disease duration in familial amyotrophic lateral sclerosis with an R521C FUS/TLS mutation.
    Suzuki N; Kato S; Kato M; Warita H; Mizuno H; Kato M; Shimakura N; Akiyama H; Kobayashi Z; Konno H; Aoki M
    J Neuropathol Exp Neurol; 2012 Sep; 71(9):779-88. PubMed ID: 22878663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FUS pathology in basophilic inclusion body disease.
    Munoz DG; Neumann M; Kusaka H; Yokota O; Ishihara K; Terada S; Kuroda S; Mackenzie IR
    Acta Neuropathol; 2009 Nov; 118(5):617-27. PubMed ID: 19830439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An autopsy case of neuronal intermediate filament inclusion disease with regard to immunophenotypic and topographical analysis of the neuronal inclusions.
    Inoue K; Fujimura H; Ueda K; Matsumura T; Itoh K; Sakoda S
    Neuropathology; 2015 Dec; 35(6):545-52. PubMed ID: 26096780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct pathological subtypes of FTLD-FUS.
    Mackenzie IR; Munoz DG; Kusaka H; Yokota O; Ishihara K; Roeber S; Kretzschmar HA; Cairns NJ; Neumann M
    Acta Neuropathol; 2011 Feb; 121(2):207-18. PubMed ID: 21052700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease.
    Cairns NJ; Zhukareva V; Uryu K; Zhang B; Bigio E; Mackenzie IR; Gearing M; Duyckaerts C; Yokoo H; Nakazato Y; Jaros E; Perry RH; Lee VM; Trojanowski JQ
    Am J Pathol; 2004 Jun; 164(6):2153-61. PubMed ID: 15161649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What's in a name? Neuronal intermediate filament inclusion disease (NIFID), frontotemporal lobar degeneration-intermediate filament (FTLD-IF) or frontotemporal lobar degeneration-fused in sarcoma (FTLD-FUS)?
    Menon R; Baborie A; Jaros E; Mann DM; Ray PS; Larner AJ
    J Neurol Neurosurg Psychiatry; 2011 Dec; 82(12):1412-4. PubMed ID: 21084263
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuronal intermediate filament inclusion disease may be incorrectly classified as a subtype of FTLD-FUS.
    Bieniek KF; Josephs KA; Lin WL; Dickson DW
    Free Neuropathol; 2020; 1():. PubMed ID: 34386806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuronal intranuclear inclusions are ultrastructurally and immunologically distinct from cytoplasmic inclusions of neuronal intermediate filament inclusion disease.
    Mosaheb S; Thorpe JR; Hashemzadeh-Bonehi L; Bigio EH; Gearing M; Cairns NJ
    Acta Neuropathol; 2005 Oct; 110(4):360-8. PubMed ID: 16025283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An autopsied case of sporadic adult-onset amyotrophic lateral sclerosis with FUS-positive basophilic inclusions.
    Matsuoka T; Fujii N; Kondo A; Iwaki A; Hokonohara T; Honda H; Sasaki K; Suzuki SO; Iwaki T
    Neuropathology; 2011 Feb; 31(1):71-6. PubMed ID: 20573033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
    Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
    Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.